ALOPEXX ENTERPRISES
Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devices
ALOPEXX ENTERPRISES
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2011-01-01
Address:
Concord, Massachusetts, United States
Country:
United States
Website Url:
http://www.alopexx.com
Total Employee:
11+
Status:
Active
Contact:
978-341-8183
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Microsoft Exchange Online Amazon
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-15 | Cognoptix | Alopexx Enterprises investment in Venture Round - Cognoptix | 1.3 M USD |
| 2014-09-30 | Cognoptix | Alopexx Enterprises investment in Series D - Cognoptix | 15 M USD |
Official Site Inspections
http://www.alopexx.com Semrush global rank: 5.83 M Semrush visits lastest month: 1.42 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Alopexx Enterprises"
Management Team :: Alopexx (ALPX)
Vaccine AV0328 was also developed by Drs. Vlock and Pier. Dr. Vlock has held his current position in Alopexx since 2021 and he has held similar positions in Alopexx's predecessor …See details»
About :: Alopexx (ALPX)
Unlike all current immune therapeutics encompassing vaccines and monoclonal antibodies that are only effective against a narrow range of microbes expressing the therapeutic’s specific antigenic target, Alopexx’s technology is directed …See details»
Alopexx - Crunchbase Company Profile & Funding
Organization. Alopexx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Alopexx partners with innovative entrepreneurs to build successful new companies. We will in …See details»
Alopexx, Inc. (ALPX) Company Profile & Facts - Yahoo Finance
See the company profile for Alopexx, Inc. (ALPX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Alopexx Company Profile - Office Locations, Competitors ... - Craft
Alopexx (ALPX, also known as Alopexx Enterprises) is a clinical-stage biotechnology company developing broad-spectrum immune-mediated therapeutics for the prevention, treatment, and …See details»
Alopexx, Inc. (ALPX) Company Profile & Overview - Stock Analysis
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express …See details»
Alopexx - Contacts, Employees, Board Members, Advisors & Alumni
Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devicesSee details»
Alopexx - Funding, Financials, Valuation & Investors - Crunchbase
Alopexx has made 2 investments. Their most recent investment was on Dec 15, 2019, when Cognoptix raised. $1.3M ... 2019, when Cognoptix raised. $1.3M. How many investments has …See details»
Alopexx - Products, Competitors, Financials, Employees, …
About Alopexx. Alopexx is a clinical-stage biotechnology company focused on developing immune therapeutics for microbial diseases. The company offers a broad-spectrum immune approach …See details»
Alopexx - VentureRadar
IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic …See details»
Board of Directors :: Alopexx (ALPX)
As CEO of Alopexx Pharmaceuticals (founded in 2006), he and co-founder Dr. Gerald Pier developed F598, a human monoclonal antibody directed against S. aureus. ... Equality Now, a …See details»
Alopexx Announces Investment from Biotech Consortia, Inc.
Sep 6, 2024 About Alopexx, Inc. Alopexx is a clinical-stage biotechnology company targeting novel immune therapeutics for the prevention and treatment of bacterial, fungal and parasitic …See details»
Sanofi-Aventis And U.S Biotechnology Company Alopexx Enter …
Dec 10, 2009 Alopexx will receive an upfront payment and research funding from sanofi-aventis and is eligible for development, regulatory and commercial milestone payments which could …See details»
Alopexx Raises $15m In IPO, Ambition To Drive Blockbuster Sales …
Oct 11, 2022 Alopexx is eyeing a $60 price point for its vaccine, which compares favourably to the $173 and $249 Pfizer charges the public and private sectors for Prevanr, according to …See details»
Alopexx, Inc. (ALPX) Stock Price, News, Quote & History - Yahoo …
Find the latest Alopexx, Inc. (ALPX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Alopexx Announces Presentation at IDWeek 2023 - PR Newswire
CAMBRIDGE, Mass., Oct. 11, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the …See details»
In the News :: Alopexx (ALPX)
Oct 11, 2023 Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328. September 06, 2024 …See details»
Alopexx, Inc. (ALPX) Stock Price, Quote & News - Stock ... - Stock …
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express …See details»
Therapeutic Solutions :: Alopexx (ALPX)
Alopexx’s proprietary immune therapeutics target the conserved microbial surface polysaccharide poly N-acetyl glucosamine (PNAG). PNAG is a critical component of the microbe’s surface …See details»